StockWatch
·
Laboratory Analytical Instruments
Quarterly ResultNov 4, 2026, 06:08 AM

Alamar Biosciences Q3 Revenue $33.5M; Net Loss $13.3M Post-IPO

AI Summary

Alamar Biosciences, Inc. filed its Form 10-Q for the period ending September 30, 2026. The company reported a significant increase in revenue to $33.5 million for the third quarter of 2026, up from $19.9 million in the same period last year. However, the net loss also widened to $13.3 million from $8.0 million, driven by increased operating expenses. A major event during the period was the company's successful initial public offering (IPO) in April 2026, which provided substantial capital. The balance sheet shows substantial growth in assets and cash reserves.

Key Highlights

  • Alamar Biosciences reported total revenue of $33.5 million for Q3 2026, an increase from $19.9 million in Q3 2025.
  • Net loss for Q3 2026 was $13.3 million, compared to a net loss of $8.0 million in Q3 2025.
  • Operating expenses increased to $35.8 million in Q3 2026 from $19.8 million in Q3 2025.
  • Cash and cash equivalents increased significantly to $121.5 million as of September 30, 2026, from $30.0 million as of December 31, 2025.
  • The company completed an initial public offering (IPO) in April 2026, raising $197.8 million in net proceeds.
  • Total assets grew to $378.0 million as of September 30, 2026, from $140.0 million as of December 31, 2025.